Cargando…

A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes

BACKGROUND: Given the multiple limitations associated with relatively homogeneous preapproval clinical trials, inadequate data disclosures, slow reaction times from regulatory bodies, and deep-rooted bias against disclosing and publishing negative results, there is an acute need for the development...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffman, Keith B., Dimbil, Mo, Kyle, Robert F., Tatonetti, Nicholas P., Erdman, Colin B., Demakas, Andrea, Chen, Dingguo, Overstreet, Brian M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397967/ https://www.ncbi.nlm.nih.gov/pubmed/26679963 http://dx.doi.org/10.18553/jmcp.2015.21.12.1134

Ejemplares similares

Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)
por: Hoffman, Keith B., et al.
Publicado: (2014)

The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010
por: Hoffman, Keith B., et al.
Publicado: (2014)

Erratum to: The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010
por: Hoffman, Keith B., et al.
Publicado: (2014)

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
por: Schotland, Peter, et al.
Publicado: (2020)

A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class
por: Hoffman, Keith B., et al.
Publicado: (2012)

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
por: Duprey, Matthew S., et al.
Publicado: (2019)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020)

Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
por: Omar, N.E., et al.
Publicado: (2021)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

A curated and standardized adverse drug event resource to accelerate drug safety research
por: Banda, Juan M., et al.
Publicado: (2016)

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
por: Sinaci, A. Anil, et al.
Publicado: (2015)

Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan
por: Okubo, TK, et al.
Publicado: (2017)

Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance
por: Park, Goeun, et al.
Publicado: (2020)

Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014–19
por: Stefanizzi, Pasquale, et al.
Publicado: (2021)

3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance
por: Vilar, Santiago, et al.
Publicado: (2015)

Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
por: Day, John W., et al.
Publicado: (2021)

14. Postmarketing Safety Experience With MenACWY-TT
por: Serra, Lidia, et al.
Publicado: (2021)

Are All Vaccines Created Equal? Using Electronic Health Records to Discover Vaccines Associated With Clinician-Coded Adverse Events
por: Boland, Mary Regina, et al.
Publicado: (2015)

Postmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity
por: Kim, Hyun Ok, et al.
Publicado: (2013)

Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
por: Misu, Takashi, et al.
Publicado: (2018)

Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
por: Day, John W., et al.
Publicado: (2021)

Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
por: Garafola, Svetlana, et al.
Publicado: (2023)

Using Postmarket Surveillance to Assess Safety-Related Events in a Digital Rehabilitation App (Kaia App): Observational Study
por: Jain, Deeptee, et al.
Publicado: (2021)

Postmarket Drug Surveillance Without Trial Costs: Discovery of Adverse Drug Reactions Through Large-Scale Analysis of Web Search Queries
por: Yom-Tov, Elad, et al.
Publicado: (2013)

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan
por: NISHIKAWA, Ryo, et al.
Publicado: (2021)

A Semantic Transformation Methodology for the Secondary Use of Observational Healthcare Data in Postmarketing Safety Studies
por: Pacaci, Anil, et al.
Publicado: (2018)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara, Michele, et al.
Publicado: (2013)

Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery
por: Kuroda, Yasufumi, et al.
Publicado: (2013)

Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases
por: Li, Xue-Lin, et al.
Publicado: (2015)

Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan
por: Kondo, Hideyuki, et al.
Publicado: (2021)

Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance
por: Yuan, Jinyi, et al.
Publicado: (2022)

Signal detection using change point analysis in postmarket surveillance(†)
por: Xu, Zhiheng, et al.
Publicado: (2015)

Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children
por: Green, Jody L., et al.
Publicado: (2018)

Postmarket Modifications of High-risk Plastic Surgery Devices
por: Olaiya, Oluwatobi R., et al.
Publicado: (2020)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
por: Ali, A. K.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_109ukjl10tdr88rikl85ogshjv